SHIONOGI's Vaccine Initiatives

SHIONOGI has identified infectious diseases as a cornerstone of our research and development efforts, and has been a pioneer in bringing groundbreaking antibacterial and antiviral medications to market. Drawing upon more than six decades of experience and expertise in infectious disease, we strive to provide a comprehensive approach to infectious disease care—encompassing epidemic prediction, prevention, diagnosis, treatment, and severity reduction. In addition, we are also working on the research and development of preventative vaccines. In June 2024, SHIONOGI obtained domestic manufacturing and marketing approval for our first recombinant protein vaccine, "COVGOZE".

In the future, we will accumulate achievements as a vaccine manufacturer by advancing the development of COVID-19 variant vaccines and influenza vaccines, while also focusing on research and development of universal vaccines and nasal vaccines to enhance competitiveness. Through these efforts, SHIONOGI aims to achieve 100 billion yen in revenue from the vaccine business by fiscal 2030 and grow it into a pillar of revenue.